cholestyramine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
727 11041-12-6

Description:

MoleculeDescription

Synonyms:

  • colestyramine
  • cholestyramine
  • cholestyramine chloride
  • colestyramin
  • Molecular weight: 1162
  • Formula: C68H97Cl5N5
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
14 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 3, 1973 FDA BRISTOL MYERS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 210.02 13.75 426 10795 625120 52712725
Product taste abnormal 88.49 13.75 28 11193 2085 53335760
Product physical consistency issue 74.05 13.75 18 11203 500 53337345
Frequent bowel movements 71.50 13.75 42 11179 14370 53323475
Bile acid malabsorption 61.33 13.75 13 11208 191 53337654
Product residue present 56.40 13.75 24 11197 4132 53333713
Product solubility abnormal 46.39 13.75 14 11207 890 53336955
Extraocular muscle paresis 46.09 13.75 10 11211 165 53337680
Colitis 46.02 13.75 50 11171 41502 53296343
Rheumatoid arthritis 39.35 13.75 9 11212 314522 53023323
Abdominal pain 38.72 13.75 130 11091 255773 53082072
Bulimia nervosa 34.77 13.75 10 11211 537 53337308
Ileal stenosis 31.71 13.75 12 11209 1524 53336321
Intestinal fibrosis 30.99 13.75 7 11214 140 53337705
Post procedural diarrhoea 29.43 13.75 7 11214 177 53337668
Toxicity to various agents 28.02 13.75 6 11215 219592 53118253
Clostridium difficile infection 26.50 13.75 31 11190 27862 53309983
Sacroiliitis 22.98 13.75 11 11210 2489 53335356
Intestinal stenosis 22.17 13.75 11 11210 2690 53335155
Suprapubic pain 20.61 13.75 7 11214 651 53337194
Product use in unapproved indication 20.56 13.75 61 11160 112228 53225617
Intestinal obstruction 19.47 13.75 27 11194 28714 53309131
Product odour abnormal 19.45 13.75 8 11213 1264 53336581
Product use complaint 18.29 13.75 9 11212 2161 53335684
Abdominal distension 18.23 13.75 47 11174 79743 53258102
Intestinal anastomosis complication 17.93 13.75 5 11216 240 53337605
Retching 17.61 13.75 18 11203 13915 53323930
Gastrointestinal wall thickening 17.06 13.75 7 11214 1099 53336746
Cystitis 16.70 13.75 33 11188 46955 53290890
Anal fistula 15.86 13.75 9 11212 2882 53334963
Gastrointestinal bacterial overgrowth 15.74 13.75 5 11216 377 53337468
White blood cell count decreased 15.17 13.75 59 11162 124416 53213429
Laboratory test abnormal 15.16 13.75 22 11199 24387 53313458
Exposure during pregnancy 15.07 13.75 59 11162 124801 53213044
Drug ineffective for unapproved indication 14.84 13.75 20 11201 20700 53317145
Flatulence 14.83 13.75 25 11196 31492 53306353
Laparotomy 14.61 13.75 4 11217 179 53337666
Jaundice 14.20 13.75 24 11197 30289 53307556
Pruritus 14.18 13.75 108 11113 293724 53044121
Mesenteric vein thrombosis 14.06 13.75 6 11215 1039 53336806
Thyroidectomy 14.06 13.75 6 11215 1040 53336805
Disorganised speech 14.00 13.75 6 11215 1051 53336794
Functional gastrointestinal disorder 13.89 13.75 9 11212 3655 53334190

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 85.43 17.34 199 5803 364603 32142921
Alveolar lung disease 64.00 17.34 15 5987 407 32507117
Pulmonary interstitial emphysema syndrome 61.65 17.34 15 5987 479 32507045
Diffuse alveolar damage 43.79 17.34 16 5986 2103 32505421
Product taste abnormal 35.73 17.34 12 5990 1230 32506294
Nerve degeneration 35.11 17.34 8 5994 191 32507333
Eosinophilic pneumonia 34.56 17.34 15 5987 3091 32504433
Hepatic enzyme abnormal 34.34 17.34 14 5988 2470 32505054
Hemivertebra 33.55 17.34 7 5995 109 32507415
Transaminases abnormal 27.77 17.34 7 5995 259 32507265
Abdominal rigidity 27.20 17.34 10 5992 1337 32506187
Bacterial diarrhoea 25.49 17.34 5 5997 56 32507468
Hyperammonaemia 25.28 17.34 15 5987 5954 32501570
Bile acid malabsorption 25.11 17.34 4 5998 11 32507513
Oesophageal atresia 23.25 17.34 7 5995 504 32507020
Enterocolonic fistula 22.79 17.34 5 5997 100 32507424
Renal mass 21.94 17.34 9 5993 1612 32505912
Small intestinal obstruction 21.28 17.34 19 5983 14177 32493347
Dehydration 21.28 17.34 62 5940 128896 32378628
Renal neoplasm 20.46 17.34 8 5994 1265 32506259
Hepatic encephalopathy 18.59 17.34 18 5984 14877 32492647
Intestinal obstruction 18.55 17.34 21 5981 20777 32486747
Eczema 18.50 17.34 18 5984 14962 32492562
Rectal haemorrhage 18.13 17.34 28 5974 37395 32470129
Product solubility abnormal 18.09 17.34 6 5996 592 32506932
Blood pressure diastolic decreased 17.99 17.34 13 5989 7184 32500340
Myalgia 17.36 17.34 43 5959 81187 32426337

Pharmacologic Action:

SourceCodeDescription
ATC C10AC01 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Bile acid sequestrants
FDA MoA N0000175365 Bile-acid Binding Activity
FDA EPC N0000180292 Bile Acid Sequestrant

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Biliary Obstruction with Pruritus indication
Poisoning by digitalis glycoside off-label use 12876009
Chronic diarrhea off-label use 236071009
Classical phenylketonuria contraindication 7573000
Constipation contraindication 14760008 DOID:2089
Hypovolemia contraindication 28560003
Blood coagulation disorder contraindication 64779008 DOID:1247
Hemorrhoids contraindication 70153002 DOID:9746
Kidney disease contraindication 90708001 DOID:557
Calculus in biliary tract contraindication 266474003
Complete Biliary Obstruction contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018811 VUID
N0000147114 NUI
D02690 KEGG_DRUG
CHEMBL2110633 ChEMBL_ID
CHEMBL1201625 ChEMBL_ID
1005 INN_ID
DB01432 DRUGBANK_ID
4B33BGI082 UNII
70695640 PUBCHEM_CID
2447 RXNORM
4435 MMSL
6264 MMSL
d00193 MMSL
001216 NDDF
387408001 SNOMEDCT_US
72824008 SNOMEDCT_US
4018811 VANDF
C0008402 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
cholestyramine light HUMAN PRESCRIPTION DRUG LABEL 1 0185-0939 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 0185-0940 POWDER, FOR SUSPENSION 4 g ORAL ANDA 19 sections
Prevalite HUMAN PRESCRIPTION DRUG LABEL 1 0245-0036 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 0245-0536 POWDER, FOR SUSPENSION 4 g ORAL ANDA 19 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 0832-0536 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine Human Prescription Drug Label 1 27241-134 POWDER, FOR SUSPENSION 4 g ORAL ANDA 20 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-265 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-266 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-267 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-269 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-270 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-271 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 49884-465 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 49884-466 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
QUESTRAN HUMAN PRESCRIPTION DRUG LABEL 1 49884-936 POWDER, FOR SUSPENSION 4 g ORAL ANDA 23 sections
QUESTRAN HUMAN PRESCRIPTION DRUG LABEL 1 49884-937 POWDER, FOR SUSPENSION 4 g ORAL ANDA 23 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3415 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-3845 POWDER, FOR SUSPENSION 4 g ORAL ANDA 12 sections
Cholestyramine Light HUMAN PRESCRIPTION DRUG LABEL 1 51224-009 POWDER, FOR SUSPENSION 4 g ORAL ANDA 23 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 51224-011 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 54868-4812 POWDER, FOR SUSPENSION 4 g ORAL ANDA 14 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5526 POWDER, FOR SUSPENSION 4 g ORAL ANDA 14 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 62559-620 POWDER, FOR SUSPENSION 4 g ORAL ANDA 20 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 63629-2161 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 63629-2162 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 63629-2163 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 63629-2164 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
cholestyramine powder for suspension Human Prescription Drug Label 1 67877-298 POWDER, FOR SUSPENSION 4 g ORAL ANDA 19 sections
Choleystyramine Light Human Prescription Drug Label 1 67877-422 POWDER, FOR SUSPENSION 4 g ORAL ANDA 19 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 68382-528 POWDER, FOR SUSPENSION 4 g ORAL ANDA 12 sections